Dementia and Alzheimer Disease

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Purple Day and epilepsy awareness.

Shae Datta, MD, a neurologist and headache specialist at NYU Langone Health, discussed the effects of traumatic brain injury and the need to accurately diagnose patients in a timely manner.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 15, 2024.

The FDA recently issued revised draft guidance to assist drug companies in developing treatments for early Alzheimer disease, focusing on diagnostic criteria, clinical staging, and outcome measures.

Tim Siegert, PhD, chief operating officer and co-founder of Allyx Therapeutics, provided commentary on the recently announced positive phase 1b results for ALX-001, an agent in development for Alzheimer and Parkinson disease.

Building on positive phase 1a data, ALX-001 demonstrated target engagement of mGluR5 receptor and maintained a safe profile across multiple doses.

The neurologist and migraine expert at NYU Langone Health provided perspective on TBI Awareness Month and the importance of accurate detection and swift care for trauamatic brain injury. [WATCH TIME: 4 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Catch up on any of the neurology news headlines you may have missed over the course of February 2024, compiled all into one place by the NeurologyLive® team.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Purple Day and epilepsy awareness.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 8, 2024.

The FDA will discuss TRAILBLAZER-ALZ 2, a large-scale phase 3 study that assessed the effects of donanemab in 1736 patients with early-stage Alzheimer disease over a 76-week period.

The director of the Multiple Sclerosis Program at the Cleveland Clinic’s Lou Ruvo Center for Brain Health talked about findings on a study comparing cognitive profiles in older patients with multiple sclerosis vs Alzheimer disease. [WATCH TIME: 5 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Catch up on any of the neurology news headlines you may have missed over the course of March 2024, compiled all into one place by the NeurologyLive® team.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Alzheimer disease and dementia.

Neurology News Network for the week ending March 1, 2024. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 1, 2024.

Caroline Just, MD, reflects on the challenges of diagnosing and treating rare neurological diseases, urging for improved education, collaboration, and research efforts.

The antisense oligonucleotide will continue to be assessed in a large-scale phase 3 study, CARDIO-TTRansform, which will have data read out in 2025.

In a recent study, a new blood test displayed remarkable accuracy in detecting Alzheimer disease pathology, showing its potential as an essential screening tool.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sleep disorders and hypersomnias.

The study suggests a potential link between poor oral health and changes in brain health, emphasizing the importance of oral care.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 23, 2024.